Several biotechnology companies with stock prices under $10 have significant catalysts anticipated for December 2024. These events could potentially impact their stock performance:
Anavex Life Sciences Corporation (AVXL): Currently trading at $8.30, Anavex is expected to release Phase 2/3 clinical trial results for its Alzheimer's disease treatment this month. Positive outcomes could enhance its market position.
BioCryst Pharmaceuticals Inc. (BCRX): With a stock price of $7.60, BioCryst anticipates FDA approval for its new oral treatment for hereditary angioedema. Approval could significantly boost its revenue prospects.
PDS Biotechnology Corporation (PDSB): Trading at $1.90, PDS Biotech is set to announce Phase 2 trial results for its HPV-related cancer immunotherapy. Favorable data may attract increased investor interest.
TG Therapeutics Inc. (TGTX): At $30.69 per share, TG Therapeutics awaits FDA decision on its multiple sclerosis drug. Approval could position it as a key player in the neurology market.
Xeris Biopharma Holdings Inc. (XERS): Priced at $3.40, Xeris expects to launch its ready-to-use glucagon injection for severe hypoglycemia. Successful commercialization could drive substantial growth.
Want To Join A Small-Cap Discord To Discuss More? Join Below:
THIS IS NOT FINANCIAL ADVICE! SEE DISCLAIMER BELOW: https://www.ztradez.net/terms-conditions DISCLOSURE: The author is not in any of the above mentioned equities.
Comments